Skip to content

7 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Diabetes is associated with increased myocardial infarction risk regardless of coronary artery disease status: a 15-year follow-up study

Prior studies with shorter follow-up have suggested that diabetes may not confer additional myocardial infarction (MI) risk in patients without coronary artery disease (CAD) as confirmed by coronary angiography - suggesting that CAD, rather than diabetes alone, drives MI risk in patients with diabetes. To...

A. Odgaard, C. Gyldenkerne, N. Sattar et al. · 0 citations
Open access Jul 2026

Prevalence and clinical correlates of metabolic dysfunction-associated steatotic liver disease in heart failure

Abstract Background The nomenclature change from non-alcoholic fatty liver disease to metabolic dysfunction-associated steatotic liver disease (MASLD) better encapsulates the associated metabolic milieu. While MASLD is associated with increased heart failure (HF) risk, characteristics and outcomes of MASLD in patients...

N. Chew, Chandramouli Chanchal, W. Tay et al. · 0 citations
Open access Oct 2026

Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis.

AIMS The impact of tirzepatide and dulaglutide on major adverse cardiovascular events (MACE) and heart failure (HF) outcomes according to HF status is unknown. METHODS AND RESULTS Patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease were treated with tirzepatide up to 15 mg or dulaglutide 1....

S. J. Nicholls, I. Pavo, Deepak L. Bhatt et al. · 0 citations
Open access Aug 2026

Targeted Assessment in High-Risk Patients With Diabetes to Identify Undiagnosed Heart Failure (TARTAN-HF).

BACKGROUND Heart failure (HF) is a common cardiovascular complication of diabetes. Early identification of unrecognized HF enables initiation of disease-modifying therapies. International diabetes and HF clinical practice guidelines are inconsistent with respect to recommendations for screening for HF in people with di...

D. Taylor-Sweet, M. Petrie, Gemma Mckinley et al. · 1 citation
Open access Aug 2026

Retatrutide‐Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes

To further characterise the effects of retatrutide on cardiometabolic risk, lipoprotein and inflammatory biomarkers were assessed post hoc in phase 2 trials of adults with obesity/overweight with or without type 2 diabetes (T2D).

G. Ruotolo, C. Harris, Yanzhu Lin et al. · 0 citations
Open access Aug 2026

Effects of Evolocumab on Mortality Outcomes in Patients Without Previous Myocardial Infarction or Stroke: A Prespecified Analysis of the VESALIUS-CV Randomized Clinical Trial.

These results support using evolocumab to improve survival in high-risk patients who have not experienced a previous myocardial infarction or stroke, including those with high-risk diabetes without qualifying atherosclerosis with low-density lipoprotein-cholesterol ≥ 90 mg/dl or apolipoprotein B ≥ 80 mg/dl.

Robert P. Giugliano, E. Bohula, A. Bellavia et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.